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Abstract
A square planar copper complex of derivatized NSAID drug (Ketoprofen
thiosemicarbazone [3-benzoyl-ct-methyl benzene acetic acid thiosemicarbazone]), s characterized
by elememal analysis, speeoscopy, electrochemistry and magnetic susceptibdity studies which
exhibits dose-dependent and enhanced antiproliferative effects on human breast cancer cell line
T47D rich in progesterone receptors.
Introduction
The pharmacology of nonsteroidal anti-inflammatory drugs (NSAIDs) and roles of
cycloo.genase enzymes, viz. COX-1 and COX-2, have now been integated into a unified
model suggesting that inhibition of both COX isoforms by NSAIDs leads to prevention
of cancers i-. 4animal model through induction of apoptosis and stimulation of immune
serveillance. The actual mechanism of this action, however, is not known.
Ketoprofen) is a widely used NSAID in clinical practice possessing a variety of
biological activities which has close structural resemblance to non-steroidal antiestrogens
viz. Trioxifene (II) and Keoxifene (Ill).
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Since II and HI have been shown to compete with estradiol for estrogen recept.
(ER) binding site and thereby prevent the growth of malignancies in breast cancers, I
may also be looked upon as a potential antacancer agent. In order to exploit ER binding
affinities of I for the purposes of evolving compounds which can deliver cytotoxic drugs to
the hormone responsive cancer cells we decided to modify ketoprofen moiety with
thiosemicarbazone functionality which has been known to attribu.. antiproliferative
properties to several organic compounds of clinical significance. Combination of
clinically used NSAIDs with cytotoxac drugs has also been shown to exert synerg, i[c effects
on the cytotoxicities ofmany anticcer drugs which is of potential clinical significance in
the treatment of certain cancers. Additionally appendage by the thiosemicarbazone
pharmacophore allows for metal conjugation especially With copper leading_ to
jancement in selective binding to the estrogen receptors as shown by Predki and Sarkar.
In the present communication we describe the synthesis and characterization of
ketoprofen thiosemicarbazone (KFTSC, IV) and its Cu (II) conjugate and evaluation of
their antiproliferative activities against human bret cancer cells T47D, which is a
progesterone receptor rich, andER sensitive cell line.
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Material and method
All chemicals used in the syntheses of lig_and and copper conjugates were of AR grade
while solvents were distilled prior to their use. Ketoprofen (Aldrich), thiosemicarbazide (Sisco
Chem. Pvt. Ltd.) and CuCI.2HO (Qualigens)were used-as supplied.
Synthesis.. ofli.and
Kdtolrofen thiosemicarbazone (IV) was prepared by reacting I (0.254g, 0.001mole) and
thiosemicarbazide (0.091g, 0.001mole) both dissolfed in methanol (10 ml) with one drop of
concentrated hydrochloric acid and bringing the reaction mixare to a reflux on the water batfi for
two hours. A white colored microc_rystallirie product separated out when the mixture was allowed
to cool. It was washed with ether and dried in vacuum.
Anal. Calc. For KFTSC (IV): %C, 6..37; %H, 5.23; /, 12.83. Found: ,/pC, 62.21; %H, 5.12;
%N, 12.81. IR (nujol),v(OH) 3166 cm -, v(C=N) 1595 cm, v(C=S) 924 cm.
S,nthesis ofCopper Complex
The ctpper complex was synthesized by refluxing the methanolic solutions of the ligand
and copper chl0ride diliydrate in 1:1 molar ratio for 25 minutes. The green precipitate of the
complex was filtered, washed with cold methanol and dried in vacuum.
Anal. Calc. For [ Cu(KFTSC)CI]: %C, 44.21; %H, 3.71; %N, 9.10; ’,Cu, 13.76. Found:%C, 44.20; %H, 3.68; %N, 9.11; %Cu, 13.72. IR (nujol); v(OH) 3167cm", v(C=N) 1571 cm, v(C=S)
903 cm."
Instruments
Elemental analyses were carried out using HOSLI CHN analyser. Infrared spectra were
recorded in KBr discs in the range of 4400-450cm- on a Perkin-Elmer 1615 FTIR insaaunent while
electronic spectra were recorded on Genesis-2 UV-VIS Speetrophotometer in the range 300-1000
nm. The magnetic susceptibility of the complex was measured at 300K on a Faraday Balance
having field strength of 7000 KG using Hg[CoCN)4] as a calibrant. Cyclic Voltammetric
measurements were made in DMF solvent on a Bioanalytical System BAS CV-27 with XY-
recorder using a platinum disc as fforking electrode against SCE and platinum wire as the reference
and au.xiliary ele.ctrodes respectixely. Tetraethyl ammonium perchlorate (TEAP) was used as a
s_upportng electrolyte.
Cll Culture
T47D cell were routinely cultured in Dulbeceo’s modified Eagle’s medium (DMEM)
7 with
phenol red, Penicillin (50 U/ml), Streptomycin (501xg/ml) and 1-0% Foetal calf serum (FCS)
(GIBCO, Myoclone). Experiments were conducted on 2cells seeded into 48 well culture plates at
densities over the range of 4000 to 10000 cells per cm. Cells were kept at 30C in an atmosphere
of5% CO2 in air.
T.rtiate..d thymdne uptake assay
T47D cells were incubated over a peri.od of 48 hours with v_aring concentrations of the test
compounds in 48 well plates. At 48 hours, [’HI thymidine was added to the cells and incubated at
37C for 2/3 hours. After removing the medium, cells were precipitated with ice cold 10%
Trichloro acetic acid (TCA) and kept at 4C for 1-2 hours. Finally, the cells were washed with ice
cold Phosphate buffered saline (PBS), to remove unbound tritium while DNA was hydrolysed with
0.5M NaOH/0.1% Triton X-100. Contents of each well were mixed with Scintillation fluid and
radioactivity was measured in Liquid Scintillation Counter.
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Figure 1. Proposed structure of complex [Cu(KFTSC)C12]
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Results and Discussion
The reaction of KFTSC with CuC12.2H20 in methanol results in a neutral, green
complex where metal coordination takes place through thione sulfur and imine mtrogen
atom as shown in Figure 1.
The IR Spectrum of the liga_nd exhibits a broadld around 3166 cm" which ,an
be .a.scrib.ed to tlie H-bonded OH bf the carboxyl group.. The strongband at 1697 cm is
attributed [o the C=O stretchin.g band of the carBoxylate group while_ the abso_rotion at
1654 cm" j# assigned to stretching frequency or 3-benzoyl carbonyl group
respectively. Condensation with thiosemicarbazone moiety results in the loss of band at
1654 cm confirming successful derivatization of the benzoyl carbonyl grouo. Two
additional bands can be seen at 3417 andl340 cm"which are due to asymmeiric and
symmetri.c, stretches, of the amin_o_ gr9u_p_." T.hle i.m.iqe v(c=aqd th,i,arbo,ny],,y(c=
tunctionalities are observed at 1595 and 924 cm whicn are slaltted to t3[i aria vu3cl
respectively on copp.er conjugation indicating their involvement in metal .o0rdination.’: The electronic spectra of IV in DMF shows a band at 31056 cm due to extended
conjugation in the thosemicarbazone moiety while its copper conjugate exhibits a
molerately intense.band at 27027 cm"due to Iigand to etal charge trans’er." Th.e broad
band observed foctlae metal-based transition at 17153 cm is attributable to a combinatiarl
of. th.e tra_nsitjons’Blg---,’.Eg an.d’B.lg "--t"Alg respectively in a. sg.u,ar,,e,,anar cqp.figumfiqn"
wlaicla is turtlaer supported by the observed magnetic moment oi .vutw IOr tins com.pex.
The cyclic voltammograms for KF.TSC and its copper com.p.]ex in DMF solvent are.siaown
in .Figure 2. The CV orofile of the cop.per complex exhibits t9’.o successive .r.educ.tion
peaks at -0.68V and -1.28V, none ofwhicti show counterparts on tiae reverse anoctic side.
Fiture 2. Cyclic voltammogr.al.S (100.mY/s) of. a 10"3M solutions of (A) KFTSC,)
[C3(KFTSCC12] in. DMF wtla inset showing tlae scan rate dependence (mV/s) Cu"
redox peak centered at +0.40V.
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igure 3. Dose:dependentDNA inhibition ofKFTSC and [Cu(KFTSC)CIz] against human
reast cancer cell hneT47D.
A comparison of these values with those observed for the parent ligands_ suggests that both
y 8,,2a.h
anodic peak appearing at +0.15V isdue to the oxidation 0halide ions.
Treatment ofKFTSC and [Cu(KFTSC)C12] with the T47D cell line shows
inhibition of DNA synthesis in a dose-dependent manner. The IC50 value of the ligand
(31xM) is lowered on complexation with copper (> 1 lxM) indicating that metal complextion
with copper clearly offers an advantage in designing antiproliferative compounds
especially against hormone responsive cancers. The selective affinity of copper ions
towards the i-ntranuclear estrogen receptor binng sites and consequent inhibition ofDNA
dimerization noted by Predki and Sarkar. may be contributing to the observed
enhancement in antiproliferative activities ofthese copper conjugates.
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